Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by RAJENDER APARASU and MICHAEL JOHNSON.
RAJENDER APARASU
Connection Strength
7.772
MICHAEL JOHNSON
  1. Real-world Comparative Effectiveness of Methotrexate-based Combinations for Rheumatoid Arthritis: A Retrospective Cohort Study. Clin Ther. 2023 09; 45(9):e177-e186.
    View in: PubMed
    Score: 0.238
  2. Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study. Clin Rheumatol. 2024 Jan; 43(1):103-116.
    View in: PubMed
    Score: 0.238
  3. Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis. Explor Res Clin Soc Pharm. 2023 Sep; 11:100296.
    View in: PubMed
    Score: 0.236
  4. Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
    View in: PubMed
    Score: 0.235
  5. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
    View in: PubMed
    Score: 0.223
  6. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study. Drugs Aging. 2022 06; 39(6):453-465.
    View in: PubMed
    Score: 0.220
  7. Risk of overactive bladder associated with cholinesterase inhibitors in dementia. J Am Geriatr Soc. 2022 03; 70(3):820-830.
    View in: PubMed
    Score: 0.212
  8. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021 08; 37(8):1303-1313.
    View in: PubMed
    Score: 0.204
  9. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis. Explor Res Clin Soc Pharm. 2021 Jun; 2:100021.
    View in: PubMed
    Score: 0.204
  10. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study. Drugs Aging. 2021 06; 38(6):493-502.
    View in: PubMed
    Score: 0.202
  11. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
    View in: PubMed
    Score: 0.202
  12. Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry. 2021 05; 36(5):684-696.
    View in: PubMed
    Score: 0.197
  13. Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis. Patient Prefer Adherence. 2020; 14:2187-2199.
    View in: PubMed
    Score: 0.197
  14. Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease. Am J Geriatr Psychiatry. 2020 10; 28(10):1079-1088.
    View in: PubMed
    Score: 0.187
  15. Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. J Gen Intern Med. 2020 07; 35(7):2084-2093.
    View in: PubMed
    Score: 0.187
  16. Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson's Disease and Comorbid Depression. Drug Healthc Patient Saf. 2020; 12:23-30.
    View in: PubMed
    Score: 0.187
  17. Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson's disease. J Psychiatr Res. 2019 10; 117:116-121.
    View in: PubMed
    Score: 0.180
  18. Anticholinergic burden and risk of cognitive impairment in elderly nursing home residents with depression. Res Social Adm Pharm. 2020 03; 16(3):329-335.
    View in: PubMed
    Score: 0.178
  19. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer. 2019 04 01; 125(7):1155-1162.
    View in: PubMed
    Score: 0.173
  20. Risk of Mortality Associated with Anticholinergic Use in Elderly Nursing Home Residents with Depression. Drugs Aging. 2017 09; 34(9):691-700.
    View in: PubMed
    Score: 0.158
  21. Risk of Mortality in Elderly Nursing Home Patients with Depression Using Paroxetine. Pharmacotherapy. 2017 03; 37(3):287-296.
    View in: PubMed
    Score: 0.152
  22. Risk of Cognitive Decline Associated With Paroxetine Use in Elderly Nursing Home Patients With Depression. Am J Alzheimers Dis Other Demen. 2016 12; 31(8):678-686.
    View in: PubMed
    Score: 0.149
  23. Discharge medication complexity and 30-day heart failure readmissions. Res Social Adm Pharm. 2017 Jul - Aug; 13(4):857-863.
    View in: PubMed
    Score: 0.148
  24. Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors. J Comp Eff Res. 2016 08; 5(5):461-73.
    View in: PubMed
    Score: 0.146
  25. Anticholinergic Medication Use and Risk of Fracture in Elderly Adults with Depression. J Am Geriatr Soc. 2016 07; 64(7):1492-7.
    View in: PubMed
    Score: 0.145
  26. Anticholinergic Medication Use and Risk of Dementia Among Elderly Nursing Home Residents with Depression. Am J Geriatr Psychiatry. 2016 06; 24(6):485-95.
    View in: PubMed
    Score: 0.142
  27. Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case-Control Study. J Am Geriatr Soc. 2016 Feb; 64(2):394-400.
    View in: PubMed
    Score: 0.141
  28. Comparative Effectiveness of Second-Generation Antidepressants in Reducing the Risk of Dementia in Elderly Nursing Home Residents with Depression. Pharmacotherapy. 2016 Jan; 36(1):38-48.
    View in: PubMed
    Score: 0.141
  29. Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension. J Alzheimers Dis. 2016; 49(2):423-32.
    View in: PubMed
    Score: 0.141
  30. Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. Am J Alzheimers Dis Other Demen. 2016 08; 31(5):395-404.
    View in: PubMed
    Score: 0.140
  31. Comparative Cognitive Profile of Second-Generation Antidepressants in Elderly Nursing Home Residents With Depression. Ann Pharmacother. 2016 Feb; 50(2):96-105.
    View in: PubMed
    Score: 0.140
  32. Potentially inappropriate anticholinergic medication use in older adults with dementia. J Am Pharm Assoc (2003). 2015 Nov-Dec; 55(6):603-612.
    View in: PubMed
    Score: 0.139
  33. Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. Drugs Aging. 2015 Sep; 32(9):743-54.
    View in: PubMed
    Score: 0.137
  34. Risk of Dementia Among Elderly Nursing Home Patients Using Paroxetine and Other Selective Serotonin Reuptake Inhibitors. Psychiatr Serv. 2015 Dec 01; 66(12):1333-40.
    View in: PubMed
    Score: 0.137
  35. Potentially inappropriate anticholinergic medication use in community-dwelling older adults: a national cross-sectional study. Drugs Aging. 2015 May; 32(5):379-89.
    View in: PubMed
    Score: 0.134
  36. Which risk-adjustment index performs better in predicting 30-day mortality? A systematic review and meta-analysis. J Eval Clin Pract. 2015 Apr; 21(2):292-9.
    View in: PubMed
    Score: 0.132
  37. Concurrent use of stimulants and second-generation antipsychotics among children with ADHD enrolled in Medicaid. Psychiatr Serv. 2015 Apr 01; 66(4):404-10.
    View in: PubMed
    Score: 0.131
  38. Application of the nonlinear Blinder-Oaxaca decomposition to study racial/ethnic disparities in antiobesity medication use in the United States. Res Social Adm Pharm. 2013 Jan-Feb; 9(1):13-26.
    View in: PubMed
    Score: 0.109
  39. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012 Sep; 8(5):437-44.
    View in: PubMed
    Score: 0.109
  40. Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure. J Comp Eff Res. 2012 Mar; 1(2):195-206.
    View in: PubMed
    Score: 0.108
  41. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study. Am J Geriatr Pharmacother. 2012 Apr; 10(2):83-94.
    View in: PubMed
    Score: 0.107
  42. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012 Mar; 21(3):233-40.
    View in: PubMed
    Score: 0.103
  43. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple-propensity analysis. Res Social Adm Pharm. 2012 Mar-Apr; 8(2):145-56.
    View in: PubMed
    Score: 0.102
  44. Risk of serious cardiac events in older adults using antipsychotic agents. Am J Geriatr Pharmacother. 2011 Apr; 9(2):120-32.
    View in: PubMed
    Score: 0.101
  45. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011 Jul; 26(7):749-57.
    View in: PubMed
    Score: 0.098
  46. Risk of falls and fractures in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. Drugs Aging. 2010 Oct 01; 27(10):815-29.
    View in: PubMed
    Score: 0.098
  47. Risk of cerebrovascular adverse events in older adults using antipsychotic agents: a propensity-matched retrospective cohort study. J Clin Psychiatry. 2010 Jun; 71(6):689-98.
    View in: PubMed
    Score: 0.095
  48. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am J Geriatr Pharmacother. 2008 Oct; 6(4):198-204.
    View in: PubMed
    Score: 0.085
  49. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin. 2008 Mar; 24(3):709-16.
    View in: PubMed
    Score: 0.081
  50. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv. 2007 Nov; 58(11):1400.
    View in: PubMed
    Score: 0.080
  51. Physician Care Coordination and the Use of Psychotropic Polypharmacy in the Management of Pediatric Mental Disorders. J Manag Care Spec Pharm. 2019 Jan; 25(1):29-38.
    View in: PubMed
    Score: 0.043
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.